A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes
Primary result · HbA1cResult — go to the resultAdjusted difference 0.11 % 95% CI −0.10 to 0.33Authors' conclusion
In adults with type 1 diabetes, HbA1c after 17 weeks with a regimen of TI and degludec was noninferior to UC, which consisted predominately of either AID or MDI. TI should be considered an option for people with type 1 diabetes, particularly those who are motivated to further reduce postprandial hyperglycemia.
Study context
- Population
- Adults with T1D, 19 sites; prestudy, automated insulin delivery (AID) used by 48% and MDI by 45%
- Participants
- 62 vs 61
- Comparison
- Inhaled Technosphere insulin plus insulin degludec vs usual care
- Technosphere insulin (TI)n = 62
- Usual care (UC)n = 61reference
Methodological detailsnoninferiority, multicentre
- Noninferiority
- Multicentre
Primary result
HbA1c · 17 weeks
Adjusted difference
0.11 %
95% CI −0.10 to 0.33
P = 0.01 for non-inferiority
By group
TIvs UC
adjusted difference 0.11 % (95% CI −0.10 to 0.33); P for non-inferiority = 0.01
As reported in the abstract
Further findings
HbA1c at baseline
HbA1c improved by >0.5% (5.5 mmol/mol) · baseline to 17 weeks
HbA1c worsened by >0.5% (5.5 mmol/mol) · baseline to 17 weeks
Safety
- Discontinued TI due to side effects
- 8 participants
- Most common TI side effect was a brief cough
Original publication
A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes. Diabetes Care. Published 6 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →